Trim14 promotes autophagy and chemotherapy resistance of gastric cancer cells by regulating AMPK/mTOR pathway

Drug Dev Res. 2020 Aug;81(5):544-550. doi: 10.1002/ddr.21650. Epub 2020 Feb 25.

Abstract

Objective: To study the relationship between TRIM14 expression and chemotherapy resistance of gastric cancer (GC) cells.

Methods: The expression of TRIM14 in 5-fluorouracil (5-FU)- and oxaliplation (L-OHP)-resistant GC tissues and cells were determined by qRT-PCR and western blotting. PcDNA3.1-TRIM14 and shRNA-TRIM14 vector were transfected to 5-FU-resistant GC cells (SGC7901/5-FU), and the proliferation and apoptosis of cells were measured. Animal experiments on 5-FU-resistant GC mice were performed to study the effect of TRIM14 expression on tumor size and weight, GC cell migration, and proliferation. pcDNA3.1-MK-3903 plasmid was transfected to SGC7901/5-FU cells with TRIM14 silence. The cell proliferation and apoptosis were determined. The protein expressions of Trim14, LC3, and BECLIN1 were measured by western blotting.

Results: TRIM14 was significantly upregulated in 5-FU- and L-OHP-resistant GC tissues and cells. The overexpression of TRIM14 promoted the proliferation and autophagy of SGC7901/5-FU cells, and inhibited the apoptosis. Moreover, in vivo experiment verified that the silence of TRIM14 reduced the tumor size and weight, and inhibited the migration and proliferation of GC cells in 5-FU-resistant GC mice. The overexpression of MK-3903 reversed the inhibiting role of TRIM14 knockout on the proliferation and autophagy of SGC7901/5-FU cells.

Conclusion: TRIM14 promoted chemotherapy resistance of GC cells by regulating AMPK/mTOR pathway, and may be a new biomarker for treating GC.

Keywords: AMPK/mTOR; TRIM14; chemotherapy resistance; gastric cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Autophagy
  • Benzimidazoles / pharmacology
  • Biphenyl Compounds / pharmacology
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation
  • Drug Resistance, Neoplasm* / genetics
  • Fluorouracil / pharmacology
  • Fluorouracil / therapeutic use
  • Humans
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Male
  • Mice, Inbred BALB C
  • Mice, Nude
  • Oxaliplatin / pharmacology
  • Oxaliplatin / therapeutic use
  • Signal Transduction
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • TOR Serine-Threonine Kinases / metabolism*
  • Tripartite Motif Proteins / genetics
  • Tripartite Motif Proteins / metabolism*

Substances

  • 5-((5-((1,1'-biphenyl)-4-yl)-6-chloro-1H-benzo(d)imidazol-2-yl)oxy)-2-methylbenzoic acid
  • Benzimidazoles
  • Biphenyl Compounds
  • Intracellular Signaling Peptides and Proteins
  • TRIM14 protein, human
  • Tripartite Motif Proteins
  • Oxaliplatin
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • AMP-Activated Protein Kinases
  • Fluorouracil